Orexo appoints Carl-Johan Blomberg as new Chief Financial Officer

Orexo appoints Carl-Johan Blomberg as new Chief Financial Officer

 

Uppsala, Sweden, August 31, 2011 - Orexo AB (STO: ORX) appoints
Carl-Johan Blomberg as new Chief Financial Officer, effective September
1. Carl-Johan Blomberg will take overall responsibility for the Group's
Finance and Administration function, including IR and IT and will be
part of the executive management team.

Carl-Johan has many years extensive experience in Finance from various
industries, such as engineering, electronics and pharmaceuticals. Most
recently he held the position of CFO at Micronic Mydata, and has earlier
held Financial Director positions within Alfa‑Laval, Procordia and
Pharmacia & Upjohn.

“We are very pleased with the recruitment of Carl-Johan as our new CFO.
He brings broad experience and will play a key role in the future
development of Orexo,” says Anders Lundström, President and CEO of Orexo
AB.

Contact details:
Anders Lundström, President and CEO, Orexo AB
Tel: +46 706 67 22 66
Email: anders.lundstrom@orexo.com (anders.lundstrom@orexo.com)

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. The company has four commercialized products,
several projects developed in partnership as well as three proprietary
development programs. Orexo's registered products are Abstral® for the
treatment of break through cancer pain, sold by Kyowa Hakko
Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill
Edluar™, sold by Meda in the USA, as well as two products for the
diagnosis of Helicobacter pylori which are being marketed by the
subsidiary Kibion. More information can be found at
www.orexo.com (http://www.orexo.com/).

Note
Orexo AB (publ) discloses the information provided in this press release
pursuant to the Securities Markets Act. The information was provided for
public release on August 31, 2011 at 11:15a.m. CET. This press release
has been prepared in both Swedish and English. In the event of any
discrepancy in the content of the two versions, the Swedish version
shall take precedence